Weekly round up from Life Sciences Industry.
U.S. Representatives Peter Welch and Francis Rooney have sent a letter to the Federal Trade Commission and the Department of Justice urging a “careful examination” of Bristol-Myers Squibb’s $74B takeout of Celgene.
The lawmakers cite the potential negative impact on competition and drug prices as the reasons for their suggested scrutiny.
Date: January 21, 2019
Source: Investor Village
Send us an email, we will get in touch with you.
Sign up for DistilINFO e-Newsletters.
CARLSMED and Precisive Surgical Announce Merger
Popit Cofounder Talks Expansion Plans, New Pharma Collaborations
New Survey Underscores Importance of Social Determinants of Health Amid COVID-19 Crisis
Yingli Pharma and MD Anderson Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs
Arsenal Capital Partners Acquires Accumen
Cleveland Clinic Names Top 10 Medical Innovations For 2021
Smith+Nephew Acquires Novel Cementless Partial Knee System
Georgia Unity | Bridging Health Gaps for Rural Communities